Cost-effectiveness analysis of camrelizumab combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma
Objective To evaluate the economics of the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma with camrelizumab in combination with a chemotherapy regimen.Methods A compartmentalized survival model was constructed to simulate patients'quality-adjusted life-years(QALY)and incremental cost-effectiveness ratios(ICER),and univariate sensitivity analyses,probabilistic sensitivity analyses,and situational analyses were performed to test the model's uncertainty.Results The results of the baseline analysis showed that the ICER for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma using camrelizumab in combination with chemotherapy regimen was 91 570.87 RMB/QALY compared with the traditional placebo combination chemotherapy regimen,which was much lower than three times the per capita GDP in China.The one-way sensitivity analysis showed that the three factors with the greatest degree of influence on the model results were progression-free survival(PFS)status utility value,cost of camrelizumab,and cost after disease progression.Probabilistic sensitivity analysis showed that when the willingness-to-pay value was greater than 150 000 RMB,the probability that camrelizumab was more economical than placebo combined with cisplatin and gemcitabine(GP regimen)was 100％.And situational analysis verified the robustness of the underlying analysis.Conclusion With a willingness-to-pay value of three times our per capita GDP,first-line treatment of recurrent or metastatic nasopharyngeal carcinoma is more economical with the use of camrelizumab in combination with a GP regimen.
nasopharyngeal carcinomacamrelizumabcost-effectiveness analysispartitioned survival modelquality adjusted life year
NETL
NSTL
万方数据
